Deucravacitinib
- Generic Name
- Deucravacitinib
- Brand Names
- Sotyktu
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O3
- CAS Number
- 1609392-27-9
- Unique Ingredient Identifier
- N0A21N6RAU
- Background
Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target. This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered cholesterol and triglyceride levels and liver and kidney dysfunction.
Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis. It was later approved by Health Canada in November 2022 and by the European Medicines Agency in March 2023.
- Indication
Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 261
- Registration Number
- NCT03920267
- Locations
- 🇷🇺
Local Institution - 0061, Ekaterinburg, Russian Federation
🇷🇴Local Institution - 0002, Ramnicu Valcea, Romania
🇺🇸Local Institution - 0114, Dallas, Texas, United States
A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 44
- Registration Number
- NCT03890770
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇭🇺Szent Imre Egyetemi Oktatokorhaz, Budapest, Hungary
🇨🇿Pharmaceutical Research Associates CZ, s.r.o, Praha 7, Czechia
An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT03890809
- Locations
- 🇭🇺
Kenezy Gyula Korhaz es Rendelointezet, Debrecen, Hungary
🇭🇺Clinical Research Unit Hungary, Miskolc, Hungary
🇨🇿Pharmaceutical Research Associates CZ, s.r.o, Praha 7, Czechia
Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT03873415
- Locations
- 🇺🇸
Scintipharma, Lexington, Kentucky, United States
A Taste Assessment of BMS-986165 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: Active Pharmaceutical Ingredient
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT03751228
- Locations
- 🇺🇸
Senopsys, Woburn, Massachusetts, United States
An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT03739788
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 131
- Registration Number
- NCT03660436
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 666
- Registration Number
- NCT03624127
- Locations
- 🇺🇸
Keck School of Medicine, Los Angeles, California, United States
🇯🇵Sapporo Skin Clinic, Sapporo, Hokkaido, Japan
🇵🇱DermoDent - Centrum Medyczne Czajkowscy, Osielsko, Poland
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1020
- Registration Number
- NCT03611751
- Locations
- 🇺🇸
Interspond - Savin Medical Group, Miami Lakes, Florida, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
- Conditions
- Granulomatous ColitisCrohn's EnteritisCrohn's DiseaseGranulomatous Enteritis
- Interventions
- Other: Placebo
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 239
- Registration Number
- NCT03599622
- Locations
- 🇺🇸
Local Institution - 0319, Chicago, Illinois, United States
🇺🇸Local Institution - 0232, Miami, Florida, United States
🇺🇸Local Institution - 0011, Las Vegas, Nevada, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.